Insight Molecular Diagnostics Inc. (IMDX): R&D Expense
$15.90M
Year ended 2025-12-31
+29.6%
3-year compound annual growth
+10.2%
5-year compound annual growth
+13.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.90M | +61.6% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $9.84M | +5.9% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $9.29M | +27.3% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $7.30M | +45.0% | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | $5.04M | -48.6% | 2023-04-12, From 2021-01-01 |
| 2020-12-31 | $9.80M | +44.2% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $6.79M | +4.3% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $6.51M | -9.2% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $7.17M | +26.4% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $5.68M | +25.4% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $4.53M | +14.3% | 2018-04-02, From 2015-01-01 |
| 2014-12-31 | $3.96M | n/a | 2017-02-27, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $15.90M | +61.6% |
| Biomerica Inc (BMRA) | 2026-05-31 | $788.0K | -23.0% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $201.3K | -55.7% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $2.88M | -11.9% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $10.08M | -30.0% |
| Celldex Therapeutics, Inc. (CLDX) | 2025-12-31 | $245.07M | +49.8% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.04M | -22.0% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $2.20M | -20.4% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $388.86M | -16.6% |
Compare IMDX, BMRA, NNNN, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗